{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:40:04Z","timestamp":1756291204252,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,7,1]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Cryoglobulinaemic vasculitis is an immune-complex-mediated, systemic inflammatory syndrome usually involving small-to-medium vessels due to precipitation of cryoglobulins at &lt;37\u00b0C. It can involve any organ but most commonly affects the skin. Associated conditions include infections (hepatitis C and HIV), haematological disorders (chronic lymphocytic lymphoma, monoclonal gammopathy of uncertain significance and multiple myeloma), autoimmune conditions (systemic lupus erythematosus and Sjogren syndrome) or as a complication following vaccination (influenza, pneumococcal and hepatitis B vaccines). Biochemical hallmarks include detection of serum cryoglobulin with low C4 levels. We describe a case of previous healthy patient with transient cryoglobulinaemic vasculitis after first dose of ChAdOx1 nCoV-19 vaccine (AstraZeneca\/Oxford).<\/jats:p>","DOI":"10.1136\/bcr-2022-250913","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:45:34Z","timestamp":1658144734000},"page":"e250913","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-5829","authenticated-orcid":false,"given":"Sadaf","family":"Ahmer","sequence":"first","affiliation":[{"name":"Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Bourke","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima Mesbah","family":"Ardakani","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2025082703272882000_15.7.e250913.1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S315727"},{"key":"2025082703272882000_15.7.e250913.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3539","article-title":"Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits","volume":"12","author":"Ravichandran","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025082703272882000_15.7.e250913.3","unstructured":"World Health Organization . WHO coronavirus (COVID-19) Dashboard. Available: https:\/\/covid19.who.int"},{"key":"2025082703272882000_15.7.e250913.4","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202005-427RL"},{"key":"2025082703272882000_15.7.e250913.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82862-5"},{"key":"2025082703272882000_15.7.e250913.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"2025082703272882000_15.7.e250913.7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"key":"2025082703272882000_15.7.e250913.8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242956"},{"key":"2025082703272882000_15.7.e250913.9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jdcr.2019.08.014","article-title":"Type II mixed cryoglobulinemia following influenza and pneumococcal vaccine administration","volume":"5","author":"Eid","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2025082703272882000_15.7.e250913.10","doi-asserted-by":"crossref","unstructured":"Guzm\u00e1n\u2010P\u00e9rez L , Puerta\u2010Pe\u00f1a M , Falkenhain\u2010L\u00f3pez D . Small\u2010vessel vasculitis following Oxford\u2010AstraZeneca vaccination against SARS\u2010CoV\u20102. J Eur Acad Dermatol Venereol 2021;35.doi:10.1111\/jdv.17547","DOI":"10.1111\/jdv.17547"},{"key":"2025082703272882000_15.7.e250913.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clicom.2021.08.001","article-title":"Pfizer\u2013biontech COVID-19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity","volume":"1","author":"Nasr","year":"2021","journal-title":"Clin Immunol Comm"},{"key":"2025082703272882000_15.7.e250913.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025082703272882000_15.7.e250913.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-250913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:27:41Z","timestamp":1756290461000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-250913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bcr-2022-250913"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-250913","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}